Proper Sequencing of Treatment for Castrate Resistant Prostate Cancer

In less than 3 years multiple new therapeutics have been approved for the treatment of metastatic castration resistant prostate cancer. The mechanisms of action as well as the modes of delivery are largely unique. Recognizing the sequencing order for these new therapies requires an understanding of the published peer reviewed literature as well as clinical judgment and experience. This article provides a review of the literature as well as guidance to assist clinicians who desire to treat metastatic castrate resistant prostate cancer.